Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness

By LabMedica International staff writers
Posted on 04 Nov 2025

Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. More...

Many patients undergo costly and taxing treatment without knowing whether it will work. Now, researchers have developed a predictive blood-based model that offers a powerful new way to determine the likelihood of treatment success.

The Liquid Biomarker of Immunotherapy Outcomes (LiBIO) score, developed by researchers at the Cancer Center at Illinois (Urbana, IL, USA), in collaboration with MD Anderson Cancer Center (Houston, TX, USA), uses a liquid biopsy—analyzing blood samples—to noninvasively monitor immune changes during immunotherapy. Their research focused on predicting patient response to immune checkpoint blockade (ICB) therapy, a widely used but inconsistently effective immunotherapy approach.

Using a mouse model of head and neck squamous cell carcinoma (HNSCC), the researchers performed serial blood analyses before and after ICB treatment to track immune system dynamics. They found that early increases in specific immune cells—particularly effector memory T cells and B cells—were closely linked to favorable treatment outcomes. This observation allowed them to identify a gene signature representing these immune populations, which now forms the basis of the LiBIO score.

The team discovered that this early post-treatment time point is critical for predicting therapeutic response. By quantifying changes in these immune cell populations, the LiBIO score successfully distinguished responders from non-responders with far greater accuracy than previous biomarkers. Remarkably, the model also proved effective across multiple cancer types, including breast, lung, and melanoma, underscoring its broad clinical potential.

Because the LiBIO score is derived from blood samples, it offers a noninvasive and easily repeatable way to monitor patient progress at the molecular level. This enables clinicians to adjust treatment strategies in real time—maximizing benefits for patients who respond while avoiding unnecessary side effects and costs for those who do not. The researchers are now working to bring the technology into human clinical trials.

“This biomarker can help identify patients who are more likely to benefit from immunotherapy, thereby improving treatment efficacy and reducing the burden of unnecessary treatment,” said Cancer Center at Illinois member Kun Wang. “Because it is blood-based, it also offers a non-invasive way to monitor treatment progress at the molecular level, which is especially valuable for real-time clinical decision-making.”

Related Links:
Cancer Center at Illinois
MD Anderson Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.